Barclays
TARS icon

Barclays’s Tarsus Pharmaceuticals TARS Stock Holding History

Barclays’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31M Buy
36,658
+8,654
+31% +$553K ﹤0.01% 2257
2026
Q1 		$1.96M Sell
28,004
-52,780
-65% -$3.69M ﹤0.01% 2365
2025
Q4 		$6.61M Sell
80,784
-11,342
-12% -$847K ﹤0.01% 2002
2025
Q3 		$5.48M Sell
92,126
-35,453
-28% -$1.75M ﹤0.01% 2124
2025
Q2 		$5.17M Buy
127,579
+74,740
+141% +$3.36M ﹤0.01% 2098
2025
Q1 		$2.71M Sell
52,839
-21,825
-29% -$1.08M ﹤0.01% 2398
2024
Q4 		$4.13M Sell
74,664
-23,999
-24% -$1.09M ﹤0.01% 2327
2024
Q3 		$3.25M Buy
98,663
+76,538
+346% +$2.15M ﹤0.01% 2452
2024
Q2 		$601K Sell
22,125
-8,183
-27% -$275K ﹤0.01% 2932
2024
Q1 		$1.1M Sell
30,308
-16,951
-36% -$498K ﹤0.01% 3042
2023
Q4 		$957K Buy
47,259
+35,622
+306% +$595K ﹤0.01% 3459
2023
Q3 		$207K Sell
11,637
-3,319
-22% -$58.7K ﹤0.01% 3281
2023
Q2 		$270K Buy
14,956
+441
+3% +$7.01K ﹤0.01% 3106
2023
Q1 		$182K Buy
14,515
+6,597
+83% +$96.5K ﹤0.01% 3848
2022
Q4 		$116K Buy
7,918
+4,157
+111% +$68.8K ﹤0.01% 4140
2022
Q3 		$64K Sell
3,761
-131
-3% -$2.08K ﹤0.01% 3703
2022
Q2 		$57K Buy
3,892
+1,299
+50% +$19.5K ﹤0.01% 3990
2022
Q1 		$44K Buy
+2,593
New +$48.1K ﹤0.01% 4165

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Barclays's TARS Position: Q2 2026 in Review

Barclays increased its Tarsus Pharmaceuticals (TARS) stake by 31% in Q2 2026, buying an estimated $553K and bringing the position to 36,658 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

Barclays first reported a position in TARS in Q1 2022 and has held it in 18 quarters since. The position peaked at $6.61M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Barclays held 36,658 shares of Tarsus Pharmaceuticals worth $2.31M as of Q2 2026.
  • Barclays bought 8,654 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $553K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2257 holding.
  • Barclays first reported a position in Tarsus Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Tarsus Pharmaceuticals position peaked at $6.61M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.